An Investigation of the Efficacy of Glycine Theophylline Sodium Extended-Release Tablets in the Treatment of Bronchial Asthma

  • Rong Fan Jingzhou First People's Hospital
  • Wei Xiao Jingzhou First People's Hospital
  • Weihua Hu Jingzhou First People's Hospital
  • Zhu Wu Jingzhou First People's Hospital
DOI: https://doi.org/10.18686/aem.v12i1.347
Keywords: Bronchial Asthma, Sodium Theophylline Glycinate, Effect Observation

Abstract

Objective: To observe the effect of treatment with theophylline extended-release tablets in patients with bronchial asthma. Methods: The medical records of 76 asthma patients admitted from 2020.8 to 2022.9 were extracted. 38 cases in the reference group received conventional basic treatment and 38 cases in the observation group received conventional + sodium theophylline glycinate treatment, and the condition control of the patients in the two groups was compared. Results: The patients in the observation group all disappeared from the disease symptoms earlier than the reference group (P < 0.05). In terms of total effective rate, the difference between the reference group and the observation group was 65.79% vs 92.11% (P < 0.05). Conclusion: Oral treatment with sodium theophylline glycinate is recommended for asthma patients to better control their condition.

References

[1] Zhao H, Zhao J. Effectiveness of glycine theophylline sodium extended-release tablets in the treatment of bronchial asthma [J]. China Medicine Herald, 2022, 19(01): 106-109.

[2] Cao YJ. Efficacy and safety of theophylline extended-release tablets in the treatment of adult bronchial asthma[J]. Psychological Monthly,2020,15(08):52-53.

[3] Qi XF, Cao Y, Wan Ruixiang. Clinical observation of 54 cases of bronchial asthma treated with theophylline extended-release tablets [J]. Shandong Pharmaceutical Industry,2003(05):48-49.
Published
2023-03-21
Issue
Vol 12, No 1(2023)
Section
Original Research Article

Copyright (c) 2023 Rong Fan, Wei Xiao, Weihua Hu, Zhu Wu

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.